immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more
immatics biotechnologies GmbH (IMTXW) - Total Liabilities
Latest total liabilities as of March 2025: $105.09 Million USD
Based on the latest financial reports, immatics biotechnologies GmbH (IMTXW) has total liabilities worth $105.09 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
immatics biotechnologies GmbH - Total Liabilities Trend (2018–2024)
This chart illustrates how immatics biotechnologies GmbH's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
immatics biotechnologies GmbH Competitors by Total Liabilities
The table below lists competitors of immatics biotechnologies GmbH ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KLASSIK RADIO N - Dusseldorf Stock Exchang
DU:KA8
|
Germany | €10.48 Million |
|
Sentry Select Primary Metals Corp
TO:PME
|
Canada | CA$179.00K |
|
7631
TW:7631
|
Taiwan | NT$607.66 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down immatics biotechnologies GmbH's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how immatics biotechnologies GmbH's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for immatics biotechnologies GmbH (2018–2024)
The table below shows the annual total liabilities of immatics biotechnologies GmbH from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $121.30 Million | -57.42% |
| 2023-12-31 | $284.88 Million | +46.35% |
| 2022-12-31 | $194.66 Million | +29.27% |
| 2021-12-31 | $150.58 Million | +0.13% |
| 2020-12-31 | $150.39 Million | -14.12% |
| 2019-12-31 | $175.11 Million | +148.42% |
| 2018-12-31 | $70.49 Million | -- |